3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Breast Neoplasms
19
Neoplasm Metastasis
9
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Recurrence
2
Pancreatic Neoplasms
2
Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Carcinoma, Renal Cell
2
Advanced Cancer
2
Unilateral Breast Neoplasms
1
Thrombocytosis
1
Solid Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Interventions
Cyclophosphamide
9
Topotecan
5
Temozolomide
5
Melphalan
5
Irinotecan
5
Busulfan
5
fludarabine
4
Granulocyte Colony-Stimulating Factor
4
Filgrastim
4
liposomal doxorubicin
3
fludarabine phosphate
3
cabozantinib
3
Vincristine
3
regorafenib
2
pegfilgrastim
2
Sirolimus
2
Doxorubicin
2
Bone Marrow Transplantation
2
trioctyl phosphine oxide
1
trifluridine tipiracil drug combination
1
thymoglobulin
1
talazoparib
1
selinexor
1
seclidemstat
1
racotumomab
1
poly ICLC
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
olaparib
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Sarcoma, Ewing
×
abemaciclib
×
Clear all
NCT02644460
2023-10-26
AflacST1501
Emory University
Phase 1
Completed
53 enrolled